The dysfunction of dopaminergic transmission has been hypothesized as a new player in the pathophysiology of Alzheimer’s disease. Crucially, dopaminergic agonist such as rotigotine showed in recent studies positive effects on cognition, as revealed by an amelioration on frontal lobe cognitive functions. The current project aims to provide clinical evidence that in Alzheimer’s disease patients chronic therapy with dopaminergic agonist such as rotigotine, administered since early stages, may slow cognitive decline and preserve functional activities. Moreover, it aims to provide relevant information about safety and tolerability of chronic therapy with Rotigotine in a large sample of Alzheimer’s disease patients. The findings of the current project will potentially enlarge the potential spectrum of existing pharmacological therapies in mild Alzheimer’s disease patients. Moreover, it will add new evidence that drugs able to potentiate dysfunctional neurotransmission could lead to relevant clinical beneficial effects. Since rotigotine is well tolerated and relatively cheap, a positive result could lead to a fast application of the present proposal to the clinical experience. Potentially the proposed project could provide a valid treatment for cognitive dysfunction in Alzheimer’s disease patients.